Go to the list of all blogs
Allana's Avatar
published in Blogs
Aug 23, 2026
Accenture (ACN) +26% Gain Over 30 Days: Recovery After the Selloff

Accenture (ACN) +26% Gain Over 30 Days: Recovery After the Selloff

Key Takeaways

  • Accenture (ACN) shares climbed roughly 26% over the past 30 days, rising from about $147 to about $185.
  • The rebound follows a sharp June selloff triggered by a slight revenue miss and trimmed guidance in its fiscal third-quarter report.
  • Renewed AI demand, a new mid-market offering, cybersecurity acquisitions, and an expanded share buyback program supported the recovery.
  • Over the trailing quarter, the stock is only modestly higher, with a deep drawdown followed by a strong rebound.
  • Wall Street consensus remains Overweight, with an average 12-month price target near $175.

Accenture (ACN) Company Overview and Market Position

Accenture plc is one of the world's largest professional services and technology consulting firms, delivering strategy, consulting, digital, technology, and operations services to clients across more than 40 industries. Its business is organized primarily around two segments, Consulting and Managed Services, with revenue diversified across financial services, health, communications, media, and the public sector. The company competes against firms such as Cognizant (CTSH), IBM (IBM), and Infosys (INFY).

Accenture's competitive strengths include its global scale, deep technology partnerships, and an expanding AI practice that employs more than 85,000 AI and data professionals. Investors follow the stock closely as a barometer of enterprise technology spending, watching for signals in new bookings, AI adoption, operating margins, and capital returns. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Accenture (ACN) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, ACN shares rose from a closing price of $146.99 on July 24, 2026, to $185.28 on August 21, 2026, a gain of approximately 26%. The advance was broad-based and marked a decisive recovery from the lows reached in late June.

On a trailing three-month basis, the move is far more modest. The stock traded near $177 to $179 in late May, meaning it is only slightly higher on net. That flat headline figure obscures significant volatility: ACN peaked near $196 in early June, fell about 18% in a single session to roughly $128 on June 18 after its fiscal third-quarter earnings report, bottomed near $124, and has since climbed steadily higher.

What Drove ACN Stock Price in the Last 30 Days

The recent rally was supported by a combination of improving fundamentals and returning investor confidence. Demand for artificial intelligence services remained a central catalyst, as management described clients moving beyond pilot programs toward full-scale AI production and noted strong advanced AI bookings. Application modernization, cloud enablement, and cybersecurity-as-a-service also contributed to managed services momentum.

Strategic initiatives reinforced the narrative. Accenture launched Accenture Edge, a mid-market offering targeting companies with roughly $300 million to $3 billion in revenue, and expanded its operational technology cybersecurity capabilities through acquisitions including Dragos, runZero, and NetRise. The company also raised its share repurchase authorization to approximately $54.1 billion, repurchased $1.2 billion of stock in the fiscal third quarter, and increased its quarterly dividend to $1.63 per share. A strong balance sheet, with about $10.2 billion in cash and cash equivalents, gave investors additional confidence.

What Drove ACN Stock Performance Over the Last Quarter

The broader quarterly narrative was defined first by a sharp selloff and then by recovery. On June 18, Accenture reported fiscal third-quarter revenue of about $18.7 billion, up roughly 6% in U.S. dollars, with adjusted earnings per share of $3.80. While earnings beat estimates, revenue came in slightly below expectations, and the company trimmed its full-year local-currency revenue growth outlook to 3% to 4% from a prior 3% to 5%. Management also cited an estimated $100 million revenue impact from Middle East conflict-related disruptions and the deferral of some large managed services contracts into fiscal 2027.

Those results amplified concerns that generative AI could disrupt demand for traditional consulting work, and the stock fell sharply. The subsequent rebound reflected renewed confidence in Accenture's positioning as an AI implementation partner, supported by partnerships with technology leaders such as Microsoft (MSFT) and Nvidia (NVDA), ongoing capital returns, and a rotation back into AI-enabler names.

ACN Stock Forecast Drivers: What Investors Should Watch Next

Looking ahead, investors will monitor Accenture's ability to convert AI demand into sustained revenue growth. The company's next earnings report, expected around October 1, 2026, will be a key checkpoint, with fourth-quarter revenue guided to a range of $17.75 billion to $18.40 billion. Full-year fiscal 2026 guidance calls for 3% to 4% local-currency revenue growth and adjusted diluted EPS of $13.78 to $13.90.

Other factors to watch include the pace of recovery in consulting demand, the anniversary of federal-services headwinds, the integration of recent acquisitions, and the path of operating margins. Macroeconomic and geopolitical uncertainty, particularly around the Middle East, remains a risk to discretionary spending, while pricing pressure and AI-related disruption of traditional IT services continue to shape the competitive landscape.

Exploring AI Trading Tools

One resource I turn to when assessing market dynamics is Tickeron’s Trending AI Robots. This section highlights top-performing bots across strategies and timeframes, offering a quick way to see which approaches are attracting attention amid moves like the one in ACN. It serves as a practical starting point for those interested in data-driven trading ideas.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ACN

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


ACN in downward trend: price may decline as a result of having broken its higher Bollinger Band on October 01, 2026

ACN broke above its upper Bollinger Band on October 01, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 33 similar instances where the stock broke above the upper band. In 24 of the 33 cases the stock fell afterwards. This puts the odds of success at 73%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for ACN moved out of overbought territory on October 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 24 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 63%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 58 cases where ACN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.

The Momentum Indicator moved above the 0 level on October 01, 2026. You may want to consider a long position or call options on ACN as a result. In 52 of 76 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.

The Moving Average Convergence Divergence (MACD) for ACN just turned positive on October 01, 2026. Looking at past instances where ACN's MACD turned positive, the stock continued to rise in 35 of 50 cases over the following month. The odds of a continued upward trend are 70%.

ACN moved above its 50-day moving average on September 29, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +19.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACN advanced for three days, in 191 of 307 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.

The Aroon Indicator entered an Uptrend today. In 129 of 192 cases where ACN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 67%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.348) is normal, around the industry mean (7.462). P/E Ratio (13.935) is within average values for comparable stocks, (67.645). Projected Growth (PEG Ratio) (1.268) is also within normal values, averaging (2.284). ACN has a moderately high Dividend Yield (0.037) as compared to the industry average of (0.010). P/S Ratio (1.618) is also within normal values, averaging (141.758).

The Tickeron SMR rating for this company is 38 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. ACN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 78 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

Notable companies

The most notable companies in this group are International Business Machines Corp (NYSE:IBM), Accenture PLC (NYSE:ACN), Unisys Corp (NYSE:UIS).

Industry description

The industry, whose total market cap runs into trillions, makes hardware/software that allows data to be stored, retrieved, transmitted, and manipulated on computers. With the ever-increasing relevance of data, the information technology (IT) industry has gained momentous growth over the years, and continues to thrive on innovation. Some of the behemoths in the industry are International Business Machines Corporation, Accenture, and VMware, Inc.

Market Cap

The average market capitalization across the Information Technology Services Industry is 8.39B. The market cap for tickers in the group ranges from 100 to 207.9B. IBM holds the highest valuation in this group at 207.9B. The lowest valued company is ARSC at 100.

High and low price notable news

The average weekly price growth across all stocks in the Information Technology Services Industry was 1%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was -1%. WYY experienced the highest price growth at 38%, while TDTH experienced the biggest fall at -33%.

Volume

The average weekly volume growth across all stocks in the Information Technology Services Industry was 45%. For the same stocks of the Industry, the average monthly volume growth was 59% and the average quarterly volume growth was -1%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 47
P/E Growth Rating: 64
Price Growth Rating: 60
SMR Rating: 73
Profit Risk Rating: 93
Seasonality Score: 8 (-100 ... +100)
View a ticker or compare two or three
ACN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

an investment holding company with interest in providing management consulting, technology and outsourcing services

Industry InformationTechnologyServices

Industry
Information Technology Services
Address
1 Grand Canal Square
Phone
+353 16462000
Employees
779000
Web
https://www.accenture.com
Interact to see
Advertisement
I've been following Planet Labs PBC (PL) closely, and one aspect that stands out is its operation of the world's largest constellation of earth-imaging satellites. This setup delivers daily global coverage, giving it a clear edge in geospatial intelligence. The "one-to-many" model allows for scalable economics, setting it apart from legacy providers that depend on exclusive image sales. The platform combines satellite data with AI-driven analytics, targeting sectors such as agriculture, defense, forestry, and insurance.
United Therapeutics Corporation focuses on biotechnology innovations for chronic and life-threatening conditions, particularly in pulmonary diseases. The company's portfolio centers on treatments for pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF), featuring products like Tyvaso (treprostinil inhalation solution), Orenitram (oral treprostinil), Remodulin, and Adcirca.
I've been following Rocket Pharmaceuticals (RCKT) closely as a late-stage biotech focused on gene therapies for rare pediatric diseases, using both lentiviral vector (LVV) and adeno-associated virus (AAV) platforms. What stands out to me is the company's strategic shift toward AAV-based cardiovascular programs—Danon disease, PKP2-ACM, and BAG3-DCM—which target areas with significant unmet needs and larger markets compared to traditional hematology indications. The recent FDA approval of KRESLADI marks Rocket's entry into commercialization, giving the team valuable launch experience and confirming the strength of its manufacturing setup.
I've been keeping an eye on KDK, and it's clear the company is well-positioned in the autonomous vehicle space, with a focus on AI-powered solutions for long-haul trucking, industrial applications, and defense. Founded in 2018 and based in Mountain View, California, Kodiak AI develops the Kodiak Driver—a modular, vehicle-agnostic virtual driver that integrates advanced AI software with hardware to enable driverless operations. This platform tackles key challenges like U.S. truck driver shortages and safety concerns, where human error accounts for over 85% of crashes.
SE stock declined -21% over the past 30 days, primarily triggered by a Q4 2025 earnings EPS miss despite revenue beat, leading to a sharp 16% single-day drop. Over the past quarter, the stock fell -37%, reflecting sustained pressure from analyst price target cuts and concerns over rising growth investments.
As I review the cybersecurity space, PANW stands out with its commanding position, holding a 28.4% share in network security as of 2024. This leadership stems from its evolution from point solutions to a unified platform that includes Strata for network security, Prisma for cloud and SASE, and Cortex for AI-powered security operations. The platformization strategy is key here—it encourages customers to consolidate their fragmented tools, which reduces complexity and costs while driving NGS ARR growth. In Q2 FY2026, NGS ARR rose 33% year-over-year to $6.3 billion.
TaskUs, Inc. (TASK) stands out as a leading provider of outsourced digital services and next-generation customer experience solutions. The company focuses on digital customer experience (Digital CX), trust and safety (monitoring user-generated content for compliance), and artificial intelligence (AI) services such as data labeling and annotation for machine learning models. From its headquarters in New Braunfels, Texas, TaskUs serves high-growth sectors like social media, e-commerce, gaming, streaming, food delivery, ride-sharing, technology, financial services, and healthcare.
WVE stock plunged approximately -52% over the past 30 days, driven primarily by disappointing high-dose data from the Phase 1 INLIGHT trial of obesity candidate WVE-007 on March 26, which erased prior gains from positive initial results. Over the past quarter, shares declined around -61%, reflecting high volatility in biotech sentiment amid clinical trial outcomes and broader sector pressures on clinical-stage firms
KOD stock surged +39% over the past 30 days, driven primarily by positive Phase 3 GLOW2 trial results for Zenkuda in diabetic retinopathy. Over the past quarter, shares gained +36%, reflecting anticipation of clinical catalysts and a successful $184 million capital raise.
Lam Research Corporation stands out as a leading supplier of semiconductor processing equipment essential for fabricating integrated circuits. The company designs, manufactures, markets, refurbishes, and services tools for deposition, etch, and clean processes, serving major chipmakers across the United States, China, Korea, Taiwan, Japan, and Europe. At its core, Lam's business revolves around innovative systems like ALTUS for film deposition and SABRE for electrochemical deposition, which are vital for advanced nodes in AI, memory, and logic chips.
Roblox Corporation (RBLX) runs a platform where millions of users create and dive into immersive 3D experiences. The business centers on a virtual economy: users buy Robux for in-game items, and creators cash out through the developer exchange (DevEx) program. In the online gaming space, Roblox stands out as a metaverse pioneer, going up against the likes of Epic Games' Fortnite and newer AI-driven platforms. The fundamentals reflect impressive user growth—daily active users (DAUs) reached 144 million in Q4 2025, a 69% jump year-over-year—but ongoing net losses underscore the heavy spending on infrastructure, AI, and safety. From what I see, this tension between growth and profitability has fueled much of the recent volatility in RBLX shares, as investors weigh strong engagement against shrinking margins.
Megan Holdings Limited (MGN) is a Malaysia-based company focused on the development, construction, maintenance, and upgrade of aquaculture and agriculture farms, along with related services. At its core, the business provides end-to-end solutions for shrimp farms, from design and building hatcheries to ongoing maintenance. It operates mainly in Sabah, Malaysia, across segments like aquaculture/agriculture, industrial solutions such as smart technologies, and investments in marketable securities.
Megan Holdings Limited (MGN), based in Kuala Lumpur and founded in 2020, focuses on developing, constructing, maintaining, and upgrading aquaculture and agriculture farms in Malaysia. The company operates in three segments—aquaculture and agriculture, industrial solutions like supplying smart technologies and machinery rentals, and investments in marketable securities—carving out a niche in engineering and construction within the Industrials sector. Its subsidiary status under Star Sprite Limited adds a layer of operational stability.
Pony AI Inc. (PONY) stands out as a leading player in autonomous mobility, dedicated to bringing self-driving technology to commercial use. Founded in 2016 and based in Guangzhou, China, the company operates across China, the U.S., and other international markets, offering robotaxi services, robotruck logistics, and licensing for intelligent driving solutions. Its business model leans heavily on asset-light partnerships with original equipment manufacturers (OEMs), transportation network companies (TNCs), and logistics platforms.
Maze Therapeutics, Inc. (MAZE) is a clinical-stage biopharmaceutical company focused on developing small-molecule precision medicines for kidney and metabolic diseases. In my view, the company's core strength lies in its proprietary Maze Compass platform, which uses human genetics and variant functionalization to identify and advance therapies targeting genetically defined patient populations.
In my view, JPM stands out as the largest U.S. bank by assets and market capitalization, commanding leading market shares across key segments. It holds approximately 11.1% of U.S. retail deposits, 23.6% of credit card sales volume, 8.4% of global investment banking fees, 11.8% of markets revenue, and 10% of treasury services revenue. This diversified "universal banking model" spans consumer and community banking, commercial and investment banking, and asset and wealth management, generating resilient revenue streams.
In recent sessions, WMT has held steady around $124, pulling back from February highs near $134. From what I see, this resilience stands out as the stock has outperformed broader indices year-to-date, thanks to its defensive role in groceries and essentials. Shoppers are leaning toward value options, and consistent volumes show ongoing institutional support. The premium valuation reflects confidence in Walmart's omnichannel progress and market share gains. Even with macro headwinds, I view WMT as a portfolio staple during uncertain times.
I've been following ANTX, a biopharmaceutical company based in Menlo Park, California, that develops novel small molecule therapeutics from its proprietary boron chemistry platform. The focus is on underserved areas like infectious diseases, with the lead candidate epetraborole advancing in Phase 3 trials for non-tuberculous mycobacterial (NTM) lung disease and acute melioidosis. The pipeline also includes AN2-502998 for chronic Chagas disease in preclinical stages, along with programs in oncology.
Tilly's, Inc. (TLYS) operates as a specialty retailer specializing in casual apparel, footwear, accessories, and hardgoods aimed at young men, women, boys, and girls. The company focuses on branded fashion inspired by action sports, surf, and skate culture, offering products like tops, bottoms, swimwear, backpacks, hats, and sunglasses from well-known brands such as Vans and Hurley. With approximately 223 stores in malls and lifestyle centers, complemented by e-commerce through www.tillys.com, Tilly's effectively combines physical and digital sales channels.
NKE shares are tumbling approximately 11% in premarket trading on April 1, 2026, sliding to near nine-year lows after the previous close of $52.82. The primary catalyst is Nike's weak Q4 fiscal 2026 guidance: management projected a 2%–4% revenue decline, sharply missing analyst expectations of approximately 1.9% growth.